The diagnosis of gastric malignant melanoma was made and the patient was scheduled to

be seen by a surgical oncologist. Two days after discharge from the outside facility, he presented to our institution with worsening fatigue and melena, his hemoglobin on presentation was 7.8. His bleeding was controlled and he underwent at PET/CT scan, dermatologic physical exam and ophthalmologic exam Inhibitors,research,lifescience,medical to evaluate for a primary melanoma. Dermatologic and ophthalmologic exam did not reveal a primary, PET/CT was only positive for a gastric mass with an SUV of 17. He was diagnosed with T4N0M0 Stage IIB primary gastric melanoma. Due to the patient’s age and functional status, he was deemed unresectable and was offered palliative Inhibitors,research,lifescience,medical radiotherapy to control bleeding and anemia. He received a dose of 16 Gy to the stomach in four fractions. Following this treatment he remained hemodynamically stable for four months; at that time he presented to the emergency department with worsening fatigue, complete blood count revealed a hemoglobin of 7.0 and patient underwent further transfusion. He was offered a second course of palliative radiotherapy during which he received an additional 9 Gy to the stomach Inhibitors,research,lifescience,medical in three fractions (Figures 1,​,2).2). At the time of this writing he has

tolerated his second course of therapy without complication. Figure 1 Beam’s eye view of the gastric melanoma target on AP X-ray. Figure 2 Axial image of AP and PA X-ray beams treating the gastric melanoma. Discussion This case documents Inhibitors,research,lifescience,medical upper GI bleeding as a clinical presentation for primary gastric melanoma, a presentation that has been documented previously (2,3); other unique presentations of primary gastric melanoma include a non-healing ulcer with benign mucosa on initial biopsy (4), and progressive Selleckchem Ibrutinib axilla swelling (18). Literature review of other cases of primary gastric melanoma and metastatic gastric melanoma reveals that the presentation

is often vague with nonspecific symptoms of anorexia, dysphagia, nausea, vomiting, epigastric Inhibitors,research,lifescience,medical pain, fatigue, and weight loss (5-7,9,19,20). The vague symptoms and nonspecific GBA3 resentation of gastric melanoma can lead to a delay in diagnosis. There is still significant controversy surrounding even the diagnosis of primary malignant melanoma of the GI tract. Arguments in support of the idea that GI melanomas are metastatic lesions even in the absence of a primary are based on the natural history of melanoma. The fact that the GI tract is the most common site of metastases of cutaneous melanoma (21) and that the stomach epithelium is devoid of melanocytes is the foundational argument supporting the assertion that all gastric melanoma is metastatic (4,8). Additionally, several cases of spontaneous regression of a primary cutaneous melanoma with subsequent visceral and nodal metastases have been reported (22,23).